Heike Luise Pahl

10PUBLICATIONS
77CO-AUTHORS
Predictive and prognostic markersHaematological tumoursMolecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Plant developmental and reproductive biology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Aug 20, 2026
A novel role for transcription factor NFE2 in redox regulation and chemotherapy resistance in acute myeloid leukemia.

|Dec 30, 2025
NFE2 Truncation Mutants Protect Wild-Type NFE2 from ITCH-Dependent Degradation.

Mirjam Elisabeth Hoeness, Franziska Zell, Titiksha Basu

|Jun 17, 2024
Oncogenic Calreticulin Induces Immune Escape by Stimulating TGFβ Expression and Regulatory T-cell Expansion in the Bone Marrow Microenvironment.

Dominik Schmidt, Cornelia Endres, Rouven Hoefflin

|Oct 04, 2023
Real-world analysis of ruxolitinib in myelofibrosis: interim results focusing on patients who were naïve to JAK inhibitor therapy treated within the JAKoMo non-interventional, phase IV trial.

Steffen Koschmieder, Susanne Isfort, Clemens Schulte

|Aug 28, 2023
GPRC5C drives branched-chain amino acid metabolism in leukemogenesis.

Yu Wei Zhang, Talia Velasco-Hernandez, Julian Mess

|Jan 28, 2023
The histone demethylase JMJD2C constitutes a novel NFE2 target gene that is required for the survival of JAK2V617F mutated cells.

Anne Marie Staehle, Jan Caspar Peeken, Georg Vladimirov

Pageof 2

Frequent Collaborators

4 joint publications

Jonas Samuel Jutzi

3 joint publications

Hans Felix Staehle

2 joint publications

Tilman Brummer

2 joint publications

Steffen Koschmieder